- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04542655
The Effect of Exercise on Serum Levels of Collagen and Proteoglycan in Patients With Knee Osteoarthritis (EFEX-OA-01) (EFEX-OA-01)
February 12, 2021 updated by: Nordic Bioscience A/S
An Open-label, Single-center, Randomized, Controlled, Exploratory Study to Investigate the Effect of Weight Bearing Versus Non-weight Bearing Exercise on Collagen and Proteoglycan in Serum and Urine in Patients With Osteoarthritis and Healthy Subjects
Aim of EFEX-OA-01: To explore how running, cycling and resting acutely influence levels of collagen and proteoglycan in patients with osteoarthritis knee and in young healthy subjects, as reflected by changes in serum and urine biochemical markers originating from joint related collagens and proteoglycans.
Study Overview
Status
Completed
Conditions
Study Type
Interventional
Enrollment (Actual)
40
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Herlev, Denmark, 2730
- Sanos Clinic
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion criteria for OA patients:
- Kellgren-Lawrence radiological grade of 1-3 in at least one tibio-femoral joint diagnosed by screening x-ray.
- 35 to < 75 years of age at the time of signing the informed consent form.
- Bodyweight > 50 and < 150 kg and a BMI in the range 18,5-35 kg/m2.
- Are male or female.
- Is able to meet for all of the four study visits and comply with the dietary and activity restrictions.
- Can give informed consent.
Exclusion criteria for OA patients:
Medical conditions:
- History of arthroscopy or intra-articular administration of corticosteroids or hyaluronic acid into the target knee within 6 months before screening.
- Kellgren-Lawrence radiological grade of 4 in at least one tibio-femoral joint
- Previous arthroplasty of knee or hip.
- Intention of having major surgery during the timeframe of this study.
- OA related to eg. dysplasia, aseptic osteonecrosis, acromegaly, Paget disease, Stickler syndrome, hemochromatosis, gout, chondrocalcinosis (pseudogout) or calcium pyrophosphate deposition disease.
- Current treatment with beta-receptor adrenergic antagonists (beta-blockers), systemic corticosteroid treatment in doses equivalent to > 10 mg of prednisolone per day, or Vitamin K antagonists, new oral anticoagulants, fractionated and non-fractionated heparin
- Active systemic infection.
- Active systemic inflammatory or autoimmune disease.
- Symptomatic occlusive arterial disease e.g. claudication intermittens.
- Heart failure > NYHA class II.
- History of transient ischaemic attack or stroke.
- ECG findings which, in the opinion of the investigator, compromises patient safety related to HRmax-test.
- History of coronary artery disease, myocardial infarction, or other serious cardiovascular disease, as evaluated by the investigator.
- Is not currently active athlete or a highly trained individual.
Inclusion criteria for healthy subjects:
- 18 to < 75 years of age at the time of signing the informed consent form.
- Have a bodyweight within > 50 and < 150 kg and a BMI within the range 18,5-35 kg/m2.
- Are male or female.
- Is able to meet for all of the four study visits and comply with the dietary and activity restrictions.
- Can give informed consent.
Exclusion criteria for healthy subjects:
- History of arthroscopy or intra-articular administration of corticosteroids or hyaluronic acid into the target knee within 6 months before screening.
- Previous arthroplasty of knee or hip.
- Intention of having major surgery during the timeframe of this study.
- Secondary OA e.g. because of dysplasia, aseptic osteonecrosis, acromegaly, Paget disease, Stickler syndrome, hemochromatosis, gout, chondrocalcinosis (pseudogout) or calcium pyrophosphate deposition disease.
- Current treatment with beta-receptor adrenergic antagonists (beta-blockers), systemic corticosteroid treatment in doses equivalent to > 10 mg of prednisolone per day, or Vitamin K antagonists, new oral anticoagulants, fractionated and non-fractionated heparin
- Any known active systemic infection.
- Any known active systemic inflammatory or autoimmune disease.
- Symptomatic occlusive arterial disease e.g. Inermittent claudication.
- Heart failure > NYHA class II.
- History of transient ischaemic attack or stroke.
- History of coronary artery disease, myocardial infarction, or other serious cardiovascular disease, as evaluated by the investigator.
- ECG findings which, in the opinion of the investigator, compromises patient safety related to HRmax-test.
- Is not currently active athlete or a highly trained individual.
- X-ray verified Kellgren-Lawrence grade 1-4.
- Is clinically suspected of having hip OA.
Other exclusions (all subjects):
- Legal incapacity or limited legal capacity
- Inability to communicate or cooperate with the investigator or to comply with the requirements of the entire study.
- Are categorized as being very difficult to draw blood from, as evaluated by the investigator.
- Current alcohol abuse and/or inability to refrain from intake of alcoholic beverages 24 hours prior to study intervention.
- Other factors e.g. self-reported drug abuse, which in the opinion of the investigator may interfere with the study conduct.
- Site staff, study staff members and study staff family members.
- Other concomitant disease compromising or otherwise significantly affecting ECM turnover in the opinion of the investigator
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: BASIC_SCIENCE
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
OTHER: Cycling first
Ergometer cycling then treadmill running then rest
|
The participants undergo ergometer cycling, treadmill running and rest.
Other Names:
The participants undergo ergometer cycling, treadmill running and rest.
Other Names:
|
OTHER: Running first
Treadmill running then ergometer cycling then rest
|
The participants undergo ergometer cycling, treadmill running and rest.
Other Names:
The participants undergo treadmill running, ergometer cycling and rest.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in biomarkers (exploratory)
Time Frame: Acute: 0-4 hours and subacute: 24 hours
|
Serum and urine biochemical markers of collagen and proteoglycan turnover
|
Acute: 0-4 hours and subacute: 24 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Henning Nielsen, MD, DMSci, Sanos Clinic
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
January 7, 2019
Primary Completion (ACTUAL)
May 14, 2019
Study Completion (ACTUAL)
May 14, 2019
Study Registration Dates
First Submitted
August 27, 2020
First Submitted That Met QC Criteria
September 2, 2020
First Posted (ACTUAL)
September 9, 2020
Study Record Updates
Last Update Posted (ACTUAL)
February 15, 2021
Last Update Submitted That Met QC Criteria
February 12, 2021
Last Verified
February 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- EFEX-OA_Protocol_Final_v1.1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Osteoarthritis, Knee
-
LifeBridge HealthMicroPort Orthopedics Inc.; Rubin Institute for Advanced OrthopedicsRecruitingKnee Osteoarthritis | Osteoarthritis, Knee | Knee Pain Chronic | Arthropathy of Knee Joint | Knee Disease | Osteoarthritis Knees Both | Osteoarthritis Knee Left | Osteoarthritis Knee RightUnited States
-
University Hospital, Clermont-FerrandSanofiCompletedKnee Osteoarthritis (Knee OA)France
-
Joseph E. BroylesCompletedDegenerative Lesion of Articular Cartilage of Knee | Degeneration; Articular Cartilage, Knee | Unilateral Primary Osteoarthritis of Knee | Osteoarthritis Knee
-
Jiangsu XinChen-Techfields Pharma Co., LTD.Completed
-
The Hong Kong Polytechnic UniversityCompleted
-
Federal University of São PauloCompletedKNEE OSTEOARTHRITISBrazil
-
Novartis PharmaceuticalsRecruitingSymptomatic Knee OsteoarthritisUnited States, Spain, Hungary, Argentina, Germany, Slovakia, Czechia, Belgium, Romania
-
University of BathUniversity of Oxford; 3D Metal Printing Ltd; Versus ArthritisRecruitingMedial Knee OsteoarthritisUnited Kingdom
-
Max Biocare Pty. Ltd.Completed
Clinical Trials on Ergometer Cycling followed by treadmill running
-
Joslin Diabetes CenterCompletedHypoglycemia | Physical Activity | Roux-en-Y Gastric Bypass | Post-bariatric HypoglycemiaUnited States
-
Poznan University of Physical EducationDavid C. Nieman; Tomasz Cisoń; Joanna Szurkowska; Mirosława Gałęcka; Dariusz Sitkowski and other collaboratorsCompleted
-
Sheba Medical CenterUnknown